Cytek Q3 revenue $51.5M (+7% YoY); net income $0.9M vs loss year ago

Cytek Biosciences, Inc.

Total revenue $51.5M, up 7% vs Q3 2023; year-to-date revenue $143.0M, up 6%.
GAAP net income $0.9M vs net loss of $6.5M in Q3 2023; adjusted EBITDA $7.6M vs $3.7M.
Installed base expanded to 2,821 units, adding 164 units in Q3.
Repurchased $12.1M of stock during Q3; cash and securities $277.8M.
FY2024 revenue guidance reaffirmed at $203-210M, expecting positive operating cash flow.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.